7 Pages
English

Revamped Therapies Preventing Visual Impairment Primed to Revolutionize US Retinal Therapeutics Market

Gain access to the library to view online
Learn more

Description

Revamped Therapies Preventing VisualRevamped Therapies Preventing Visual Impairment Primed to Revolutionize US Retinal Therapeutics Market PR Newswire MOUNTAIN VIEW, California, Jan. 8, 2014 -- Frost & Sullivan: Ripe for innovative, non-invasive treatments, the market will almost double by 2017 The need for effective and patient-friendly treatment of retinal diseases to avoid visual impairment is driving the retinal therapeutics market in the U.S. Vascular endothelial growth factor (VEGF) inhibitors dominate the market as they are a safe and effective option to treat age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). Although highly efficacious, existing VEGF treatments require frequent, invasive intravitreal injections. Thus, growth opportunities exist for new therapies with comparable efficacy but improved dosing and administration. New analysis from Frost & Sullivan's (http://www.lifesciences.frost.com) Analysis of the US Retinal Therapeutics Market finds the market earned revenue of $2.45 billion in 2012 and estimates this to almost double to $4.15 billion in 2017. For more information on this research, please email Jennifer Carson, Corporate Communications, at jennifer.carson@frost.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country. "Despite the popularity of VEGF inhibitors in the U.S.

Subjects

Informations

Published by
Published 08 January 2014
Reads 13
Language English
Revamped Therapies Preventing Visual Impairment Primed to Revolutionize US Retinal Therapeutics Market

PR Newswire

-- Frost & Sullivan: Ripe for innovative, non-invasive treatments, the market will almost double by 2017

The need for effective and patient-friendly treatment of retinal diseases to avoid visual impairment is driving the retinal therapeutics market in the U.S. Vascular endothelial growth factor (VEGF) inhibitors dominate the market as they are a safe and effective option to treat age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). Although highly efficacious, existing VEGF treatments require frequent, invasive intravitreal injections. Thus, growth opportunities exist for new therapies with comparable efficacy but improved dosing and administration.